GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chongqing Genrix Biopharmaceutical Co Ltd (SHSE:688443) » Definitions » Book Value per Share

Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Book Value per Share : ¥5.46 (As of Mar. 2025)


View and export this data going back to 2023. Start your Free Trial

What is Chongqing Genrix Biopharmaceutical Co Book Value per Share?

Chongqing Genrix Biopharmaceutical Co's book value per share for the quarter that ended in Mar. 2025 was ¥5.46.

During the past 12 months, Chongqing Genrix Biopharmaceutical Co's average Book Value Per Share Growth Rate was -24.80% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 72.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Chongqing Genrix Biopharmaceutical Co was 72.30% per year. The lowest was 72.30% per year. And the median was 72.30% per year.

Chongqing Genrix Biopharmaceutical Co's current price is ¥28.77. Its book value per share for the quarter that ended in Mar. 2025 was ¥5.46. Hence, today's PB Ratio of Chongqing Genrix Biopharmaceutical Co is 5.27.

During the past 6 years, the highest P/B Ratio of Chongqing Genrix Biopharmaceutical Co was 5.85. The lowest was 3.30. And the median was 4.45.


Chongqing Genrix Biopharmaceutical Co Book Value per Share Historical Data

The historical data trend for Chongqing Genrix Biopharmaceutical Co's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chongqing Genrix Biopharmaceutical Co Book Value per Share Chart

Chongqing Genrix Biopharmaceutical Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Book Value per Share
Get a 7-Day Free Trial - 1.13 0.11 7.59 5.80

Chongqing Genrix Biopharmaceutical Co Quarterly Data
Dec19 Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.25 6.82 6.42 5.80 5.46

Competitive Comparison of Chongqing Genrix Biopharmaceutical Co's Book Value per Share

For the Biotechnology subindustry, Chongqing Genrix Biopharmaceutical Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chongqing Genrix Biopharmaceutical Co's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chongqing Genrix Biopharmaceutical Co's PB Ratio distribution charts can be found below:

* The bar in red indicates where Chongqing Genrix Biopharmaceutical Co's PB Ratio falls into.


;
;

Chongqing Genrix Biopharmaceutical Co Book Value per Share Calculation

Chongqing Genrix Biopharmaceutical Co's Book Value Per Share for the fiscal year that ended in Dec. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(2,126.04-0.00)/366.68
=5.80

Chongqing Genrix Biopharmaceutical Co's Book Value Per Share for the quarter that ended in Mar. 2025 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(2,000.63-0.00)/366.68
=5.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Chongqing Genrix Biopharmaceutical Co  (SHSE:688443) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Chongqing Genrix Biopharmaceutical Co Book Value per Share Related Terms

Thank you for viewing the detailed overview of Chongqing Genrix Biopharmaceutical Co's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Chongqing Genrix Biopharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No. 699, Maliu Avenue, Area A, Building 2, International Bio City, Banan, Chongqing, CHN, 401338
Chongqing Genrix Biopharmaceutical Co Ltd is engaged in the research & development, production and sales of antibody drugs. The company has a total of more than ten products under research covering three major therapeutic areas. The progress of core products is leading, and some product pipelines are as follows; autoimmune disease, infectious disease, and tumor. Its product Xeligekimab injection (Xeligekimab) is a recombinant fully human anti-IL-17A monoclonal antibody independently developed by the company, which has been accepted by the National Medical Products Administration (NMPA) for new drug marketing applications.
Executives
Jiang Ren Sheng Director

Chongqing Genrix Biopharmaceutical Co Headlines

No Headlines